^
Association details:
| Biomarker: | FLT3 I836 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Excerpt:
...Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type signal ratio 4....
Trial ID:
Source:
Title:
A CASE OF IDH1 MUTATED AML IN AN ADULT PATIENT AFFECTED BY OLLIER DISEASE, BIOLOGICAL SPECULATIONS AND CLINICAL IMPLICATIONS
Published date:
05/12/2021
Excerpt:
...a 35 years old man was admitted to our unit with haemorrhagic symptoms….A bone marrow evaluation led to a diagnosis of AML, FAB M2, with normal karyotype, NPM1 exon 11 (W288Cfs*12), FLT3 TKD (D835Y and I836del) and IDH1 (R132H) mutation. An induction chemotherapy with “7+3” associated with midostaurin (days 8-21) was administered and complete remission was obtained.
Secondary therapy:
7+3 (DAC)
